Can Fite (Israel) Today
| CANF Stock | 2.10 0.20 10.53% |
PerformanceModest
| Odds Of DistressAbove Average
|
Can Fite is trading at 2.10 as of the 21st of March 2025, a 10.53 percent increase since the beginning of the trading day. The stock's open price was 1.9. Can Fite has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. The company has 1.01 B outstanding shares. More on Can Fite Biopharma
Moving against Can Stock
Can Fite Biopharma cannot be verified against its exchange. It appears that Can Fite is not available for investing at the moment. Please verify the symbol is currently traded on Tel Aviv Stock Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
RefreshCan Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Can Fite's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Can Fite or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Director | Pnina Fishman |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Can Fite Biopharma (CANF) is traded on Tel Aviv Stock Exchange in Israel and employs 8 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Can Fite's market, we take the total number of its shares issued and multiply it by Can Fite's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Can Fite Biopharma operates under Biotechnology sector and is part of Health Care industry. The entity has 1.01 B outstanding shares.
Can Fite Biopharma has accumulated about 3.21 M in cash with (9.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Check Can Fite Probability Of Bankruptcy
Can Fite Biopharma Risk Profiles
Although Can Fite's alpha and beta are two of the key measurements used to evaluate Can Fite's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.81 | |||
| Semi Deviation | 3.81 | |||
| Standard Deviation | 5.05 | |||
| Variance | 25.55 |
Can Stock Against Markets
Try Other Suggestions
Be your own money manager
Our tools can tell you how much better you can do entering a position in Can Fite without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Can Fite Corporate Management
Elected by the shareholders, the Can Fite's board of directors comprises two types of representatives: Can Fite inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Can. The board's role is to monitor Can Fite's management team and ensure that shareholders' interests are well served. Can Fite's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Can Fite's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Motti Farbstein | Chief Officer | Profile | |
| Sari Fishman | VP Devel | Profile | |
| Ilan Cohn | CoFounder Chairman | Profile | |
| FACP FACR | Clinical Advisor | Profile |
Additional Information and Resources on Investing in Can Stock
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.